Efficacy of cilostazol in canine bradyarrhythmia
Recently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs wi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Veterinary Science |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fvets.2022.954295/full |
| _version_ | 1818487123287736320 |
|---|---|
| author | Takahiro Ohmori Yuri Matsumura Aritada Yoshimura Shohei Morita Hiroshi Hasegawa Daiki Hirao Ryuji Fukushima |
| author_facet | Takahiro Ohmori Yuri Matsumura Aritada Yoshimura Shohei Morita Hiroshi Hasegawa Daiki Hirao Ryuji Fukushima |
| author_sort | Takahiro Ohmori |
| collection | DOAJ |
| description | Recently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs with bradyarrhythmia in Japan. Dogs that had been brought to the Tokyo University of Agriculture and Technology Animal Medical Center and 23 veterinary hospitals in Japan and been treated with cilostazol initially as the only therapeutic strategy for bradyarrhythmia between January 2010 and August 2021 were included in this study. Survival analyses were performed using Cox proportional hazards analysis, the log-rank test, and the generalized Wilcoxon test to evaluate the efficacy of cilostazol. Fifty-nine privately owned dogs were included in this study. In the survival time analysis, the risk of death was significantly lower and the survival rate was higher in cases in which cilostazol was administered at 10 mg/kg or more per dose. A third-degree atrioventricular block also significantly increased the risk of death and was associated with a lower survival rate. However, in some patients with a third-degree atrioventricular block, there was an increase in the ventricular rate and improvement in clinical symptoms without disappearance or decrease of the atrioventricular block. This study had several important findings that have not previously been reported concerning the use of cilostazol for canine bradyarrhythmia, including the appropriate dose in a clinical setting and the efficacy and prognosis according to the type of bradyarrhythmia. |
| first_indexed | 2024-12-10T16:33:09Z |
| format | Article |
| id | doaj.art-ab264525f74d4cf4b9277ec1399c280b |
| institution | Directory Open Access Journal |
| issn | 2297-1769 |
| language | English |
| last_indexed | 2024-12-10T16:33:09Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Veterinary Science |
| spelling | doaj.art-ab264525f74d4cf4b9277ec1399c280b2022-12-22T01:41:30ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692022-08-01910.3389/fvets.2022.954295954295Efficacy of cilostazol in canine bradyarrhythmiaTakahiro OhmoriYuri MatsumuraAritada YoshimuraShohei MoritaHiroshi HasegawaDaiki HiraoRyuji FukushimaRecently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs with bradyarrhythmia in Japan. Dogs that had been brought to the Tokyo University of Agriculture and Technology Animal Medical Center and 23 veterinary hospitals in Japan and been treated with cilostazol initially as the only therapeutic strategy for bradyarrhythmia between January 2010 and August 2021 were included in this study. Survival analyses were performed using Cox proportional hazards analysis, the log-rank test, and the generalized Wilcoxon test to evaluate the efficacy of cilostazol. Fifty-nine privately owned dogs were included in this study. In the survival time analysis, the risk of death was significantly lower and the survival rate was higher in cases in which cilostazol was administered at 10 mg/kg or more per dose. A third-degree atrioventricular block also significantly increased the risk of death and was associated with a lower survival rate. However, in some patients with a third-degree atrioventricular block, there was an increase in the ventricular rate and improvement in clinical symptoms without disappearance or decrease of the atrioventricular block. This study had several important findings that have not previously been reported concerning the use of cilostazol for canine bradyarrhythmia, including the appropriate dose in a clinical setting and the efficacy and prognosis according to the type of bradyarrhythmia.https://www.frontiersin.org/articles/10.3389/fvets.2022.954295/fullcilostazolbradyarrhythmiacaninepacemaker implantationsick sinus syndrome |
| spellingShingle | Takahiro Ohmori Yuri Matsumura Aritada Yoshimura Shohei Morita Hiroshi Hasegawa Daiki Hirao Ryuji Fukushima Efficacy of cilostazol in canine bradyarrhythmia Frontiers in Veterinary Science cilostazol bradyarrhythmia canine pacemaker implantation sick sinus syndrome |
| title | Efficacy of cilostazol in canine bradyarrhythmia |
| title_full | Efficacy of cilostazol in canine bradyarrhythmia |
| title_fullStr | Efficacy of cilostazol in canine bradyarrhythmia |
| title_full_unstemmed | Efficacy of cilostazol in canine bradyarrhythmia |
| title_short | Efficacy of cilostazol in canine bradyarrhythmia |
| title_sort | efficacy of cilostazol in canine bradyarrhythmia |
| topic | cilostazol bradyarrhythmia canine pacemaker implantation sick sinus syndrome |
| url | https://www.frontiersin.org/articles/10.3389/fvets.2022.954295/full |
| work_keys_str_mv | AT takahiroohmori efficacyofcilostazolincaninebradyarrhythmia AT yurimatsumura efficacyofcilostazolincaninebradyarrhythmia AT aritadayoshimura efficacyofcilostazolincaninebradyarrhythmia AT shoheimorita efficacyofcilostazolincaninebradyarrhythmia AT hiroshihasegawa efficacyofcilostazolincaninebradyarrhythmia AT daikihirao efficacyofcilostazolincaninebradyarrhythmia AT ryujifukushima efficacyofcilostazolincaninebradyarrhythmia |